Abstract: Objective To evaluate the clinical efficacy and safety of paclitaxel plus cisplatin chemotherapy combining concurrent radiotherapy on esophageal carcinoma. Methods We searched PubMed,EMBASE,Cochrane Library,CNKI,and other databases to collect randomized controlled trials (RCTs).According to the statistical analysis of RevMan5.0 statistical software. ResultsThe results were included in six randomized controlled trials,including 559 cases of patients.Meta analysis showed that in the treatment of advanced esophageal carcinoma,when compared with radiotherapy alone,the concurrent radiotherapy and chemotherapy can improve the efficiency,the RR value and 95% confidence interval were 1.28(1.17,1.40) and 1,2 or 3-year survival rate of RR values and 95% confidence interval are 1.25 (1.10,1.42),1.44(1.18,1.76),1.46(1.15,1.86),respectively.However,the toxicities also increased,such as the incidence of radioactive esophagitis and gastrointestinal adverse reactions were 2.49(1.02,6.08),25.00 (3.49,179.25),respectively. Conclusion The efficacy of pacli taxol plus cisplatin combined with concurrent radiotherapy on esophageal carcinoma is more effective than that of concurrent radiotherapy alone.Although the adverse reactions are increased at the same time,most of them can be tolerated.